Comparison of Fixed Dosing vs Train of Four Titration of Cisatracurium in COVID-19 ARDS Patients
Journal of Pharmacy Practice · 2024
DOI: 10.1177/08971900231220438 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Pharmacy Practice, 2024. Verfasst von Oyshik Banerjee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus, OH, USA. Hauptthemen laut MEDLINE: Atracurium, Respiratory Distress Syndrome, Neuromuscular Blocking Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Background
Early neuromuscular blockade with cisatracurium has been associated with improved outcomes in moderate-severe acute respiratory distress syndrome (ARDS). Previous studies have demonstrated increased drug utilization without benefits in oxygenation using fixed dose cisatracurium compared to train-of-four (TOF) titration.
Objective
We sought to compare a novel, lower fixed dose cisatracurium protocol to TOF titration evaluating the impact on PaO2:FiO2 ratio (P/F).
Methods
We conducted a single-center retrospective cohort study comparing fixed dose cisatracurium to TOF titration. We included patients aged 18-89 treated for COVID-19 ARDS with a baseline P/F≤200 who received a cisatracurium infusion for ≥12 h. The primary outcome was change in P/F at 48 h from baseline. Secondary outcomes included change in P/F at 24 h and 7 days, need for mechanical ventilation at day 28, and cisatracurium utilization.
Results
Analyses included 125 patients (fixed dose = 65, TOF = 60). Severe ARDS was common with a baseline median P/F of 73.7 vs 79.5, P = .133. The change in P/F at 48 h was larger in the TOF cohort in the adjusted analysis (24.9 vs 70.8, P < .005). The rate and total cumulative dose of cisatracurium were higher in the fixed dose cohort (5 vs 3 mcg/kg/min, P < .001; 1034 vs 612 mg, P < .001) despite similar infusion durations (44.1 h vs 48.5 h, P = .642).
Conclusions
Patients in the TOF cisatracurium cohort had improved P/F at 48 h compared to the fixed dose cohort, while also using only 60% of the cumulative dose. Future directions should include analysis of the implications of increased cisatracurium exposure on patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
- Department of Pharmacy, MetroHealth Medical Center, Cleveland, OH, USA.
- Division of Pulmonary, Critical Care, and Sleep Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
- Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA.
ORCID-Profile: Oyshik Banerjee, Kari M Cape
Zitieren
APA
Banerjee, O., Elefritz, J. L., Doepker, B. A., Atyia, S. A., Brummel, N. E., Smith, R. M., Handley, D., & Cape, K. M. (2024). Comparison of Fixed Dosing vs Train of Four Titration of Cisatracurium in COVID-19 ARDS Patients. Journal of Pharmacy Practice. https://doi.org/10.1177/08971900231220438
Vancouver
Banerjee O, Elefritz JL, Doepker BA, Atyia SA, Brummel NE, Smith RM, et al. Comparison of Fixed Dosing vs Train of Four Titration of Cisatracurium in COVID-19 ARDS Patients. Journal of Pharmacy Practice. 2024. doi:10.1177/08971900231220438
BibTeX
@article{Banerjee2024,
author = {Banerjee, Oyshik and Elefritz, Jessica L and Doepker, Bruce A and Atyia, Sara A and Brummel, Nathan E and Smith, Rachel M and Handley, Demond and Cape, Kari M},
title = {Comparison of Fixed Dosing vs Train of Four Titration of Cisatracurium in COVID-19 ARDS Patients},
journal = {Journal of Pharmacy Practice},
year = {2024},
doi = {10.1177/08971900231220438}
}
EUVIMED